Affinage

DACT2

Dapper homolog 2 · UniProt Q5SW24

Length
774 aa
Mass
82.7 kDa
Annotated
2026-06-09
37 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DACT2 is a cytoplasmic negative regulator of developmental signaling that restrains both the Wnt/β-catenin and TGF-β/Nodal pathways, with consequences for epithelial morphogenesis, fibrosis, and tumor suppression (PMID:17197390, PMID:22806826). It dampens TGF-β signaling by targeting the type I receptor ALK5 for lysosomal degradation, limiting Smad2 phosphorylation, and these activities control collecting duct morphogenesis and oppose fibrotic differentiation (PMID:17197390, PMID:20685821, PMID:36481337, PMID:35818217). On the Wnt axis DACT2 suppresses TCF/LEF transcriptional output by promoting β-catenin phosphorylation and reducing β-catenin levels, and it physically interacts with the transcription factor PITX2 to repress PITX2-driven Wnt target activation within a reciprocal feedback loop (PMID:23349981, PMID:25375359, PMID:30359298). Downstream of Wnt/β-catenin it also blocks YAP nuclear translocation, sequestering YAP in the cytoplasm for degradation (PMID:28796248). DACT2 expression is positively controlled by promoter demethylation through the dioxygenase TET1 and by allele-specific binding of the transcription factor TFAP2A, and it is frequently silenced by promoter CpG hypermethylation across lung, liver, thyroid, gastric, esophageal, and nasopharyngeal cancers, where its restoration suppresses proliferation, migration, invasion, EMT, and xenograft growth (PMID:22806826, PMID:23449122, PMID:30075814, PMID:31866302). In vivo loss of Dact2 de-represses EMT-related genes and a β-catenin/Igf1-MAPK axis, confirming its physiological role as a brake on these pathways (PMID:31983425, PMID:37603122).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2003 Low

    Established DACT2 as a DVL-binding family member structurally equipped to participate in Wnt signaling, framing the protein's candidate function before any direct assay.

    Evidence Bioinformatic/evolutionary characterization identifying conserved DAPH domains including a leucine zipper and PDZ-binding motif

    PMID:12632086

    Open questions at the time
    • Computational prediction only, no experimental validation of DVL binding or function
    • No demonstration of endogenous activity
  2. 2006 Medium

    Answered how DACT2 acts on TGF-β signaling by showing it drives lysosomal degradation of the ALK5 receptor, defining a conserved receptor-level mechanism of pathway antagonism.

    Evidence Mouse Dact2 overexpression with Smad-reporter assays, receptor degradation assays, and zebrafish embryo overexpression

    PMID:17197390

    Open questions at the time
    • Mechanism of how DACT2 recruits ALK5 to lysosomes not defined
    • Based on overexpression, not endogenous loss-of-function
  3. 2010 Medium

    Placed Dact2 in a developmental context by showing endogenous loss elevates phospho-Smad2 and disrupts collecting duct morphogenesis, demonstrating a physiological TGF-β brake.

    Evidence siRNA knockdown in collecting duct cells with phospho-Smad2 immunoblot, wound-healing, 3D morphology and immunofluorescence

    PMID:20685821

    Open questions at the time
    • Connection to ALK5 degradation in this tissue not directly tested
    • No in vivo genetic confirmation in kidney
  4. 2013 Medium

    Defined DACT2 as an epigenetically silenced Wnt-pathway tumor suppressor and established its mechanism of repressing TCF/LEF activity and β-catenin in cancer.

    Evidence Methylation-specific PCR, TCF/LEF and TCF-4 reporter assays, siRNA, cell cycle analysis and xenografts in lung and hepatocellular carcinoma

    PMID:22806826 PMID:23449122

    Open questions at the time
    • Direct molecular target on the Wnt axis not pinned down
    • Each cancer characterized by single lab
  5. 2013 Medium

    Identified a direct physical partner, showing DACT2 binds PITX2 to repress PITX2-driven Wnt target transcription within a feedback loop, giving a transcription-factor-level mechanism.

    Evidence Co-immunoprecipitation, Topflash reporter, loss/gain-of-function and immunohistochemistry in odontogenesis

    PMID:23349981

    Open questions at the time
    • Interaction domain mapping absent
    • Generality of PITX2 repression beyond tooth development untested
  6. 2014 Medium

    Clarified where in the Wnt cascade DACT2 acts by showing it increases β-catenin phosphorylation and functions upstream of the TCF/LEF complex, with effects reversed by Dvl2.

    Evidence TCF/LEF reporter, western blot for phospho-β-catenin, co-transfection with Dvl2 and invasion assays in thyroid and gastric cancer

    PMID:25375359 PMID:25520862

    Open questions at the time
    • Kinase responsible for β-catenin phosphorylation not identified
    • Noncanonical Wnt mechanism not resolved
  7. 2016 Medium

    Broadened DACT2's antagonism to additional pathways, showing it opposes Akt/GSK-3 and EMT alongside Wnt, linking it to apoptosis and metastatic phenotypes.

    Evidence Ectopic expression, apoptosis/migration assays, EMT marker and pathway western blots plus xenografts in breast and esophageal cancer

    PMID:26919254 PMID:27708215

    Open questions at the time
    • Direct interaction with Akt/GSK-3 components not shown
    • EMT regulation mechanism downstream of which pathway unclear
  8. 2017 Medium

    Extended DACT2 downstream output to the Hippo effector YAP, showing it blocks YAP nuclear translocation and promotes its cytoplasmic degradation via Wnt/β-catenin.

    Evidence Overexpression/knockdown, nuclear/cytoplasmic fractionation, western blot and xenograft in glioma

    PMID:28796248

    Open questions at the time
    • Direct versus indirect control of YAP not distinguished
    • Link between β-catenin phosphorylation and YAP retention unresolved
  9. 2018 Medium

    Identified upstream regulators of DACT2, establishing that TET1-mediated promoter demethylation restores its expression to antagonize Wnt, and that it enforces G2/M arrest via β-catenin/Cdc25c.

    Evidence Ectopic TET1 expression with MSP, RT-PCR, reporter assays and chemosensitivity testing in nasopharyngeal carcinoma

    PMID:30075814 PMID:30359298

    Open questions at the time
    • Whether TET1 acts directly at the DACT2 locus not shown by ChIP
    • Cdc25c regulation mechanism downstream of β-catenin incomplete
  10. 2019 Medium

    Defined transcriptional activation of DACT2 by showing allele-specific TFAP2A binding at a promoter SNP controls its expression level.

    Evidence Luciferase reporter, EMSA and genotyping with expression analysis in NSCLC

    PMID:31866302

    Open questions at the time
    • In vivo relevance of the SNP for cancer risk not established
    • Interplay between TFAP2A activation and methylation silencing untested
  11. 2020 Medium

    Provided in vivo genetic confirmation that Dact2 restrains EMT-related gene expression and tissue homeostasis, and explored its role in cardiac β-catenin and TGF-β regulation.

    Evidence CRISPR-Cas9 knockout zebrafish with EMT gene RT-PCR and histology; overexpression in cardiac cells and atrial fibroblasts

    PMID:31983425 PMID:32642106

    Open questions at the time
    • Cardiac findings rest on single overexpression approach (Low confidence)
    • Direct targets driving EMT phenotype not identified
  12. 2022 Medium

    Revealed a metabolic dimension of DACT2's TGF-β antagonism by showing it directs lysosomal degradation of LDHA to suppress glycolysis and myofibroblast differentiation, and inhibits liver fibrosis.

    Evidence AAV6 overexpression in vivo, LDHA degradation and lysosome colocalization, metabolic flux assays in lung fibrosis; lentiviral overexpression in CCl4 liver fibrosis model

    PMID:35818217 PMID:36481337

    Open questions at the time
    • How DACT2 selectively targets LDHA to lysosomes not defined
    • Liver fibrosis data limited to overexpression with western blot (Low confidence)
  13. 2023 Medium

    Connected Dact2 loss to a defined transcriptional output in vivo, showing β-catenin directly binds and activates Igf1 in the absence of Dact2, driving a MAPK-dependent injury response.

    Evidence Dact2 KO mouse with RNA-seq, ChIP/β-catenin binding to Igf1, Igf1 knockdown and Wnt agonist rescue in cisplatin nephrotoxicity

    PMID:37603122

    Open questions at the time
    • How Dact2 mechanistically gates β-catenin occupancy at Igf1 not shown
    • Generality of the Igf1-MAPK axis beyond kidney injury untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • The biochemical mechanism by which DACT2 selects and routes its targets (ALK5, LDHA) to lysosomes, and the identity of the kinase/complex through which it promotes β-catenin phosphorylation, remain unresolved.
  • No structural model of DACT2 in complex with any partner
  • Degradation adaptor machinery linking DACT2 to lysosomes unidentified
  • Direct biochemical demonstration of DACT2-induced β-catenin phosphorylation absent

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 3 GO:0060090 molecular adaptor activity 1
Localization
GO:0005829 cytosol 1
Pathway
R-HSA-1643685 Disease 4 R-HSA-162582 Signal Transduction 3
Partners
ALK5CTNNB1DVL2LDHAPITX2YAP

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Human DACT2 (DAPPER2) was identified as containing seven conserved DAPH domains including a leucine zipper (DAPH2), serine-rich region (DAPH3), and C-terminal PDZ-binding motif (DAPH7), establishing it as a DVL-binding protein homolog involved in WNT signaling. Bioinformatics/in silico characterization with evolutionary analysis International journal of oncology Low 12632086
2006 Mouse Dact2 (mDpr2) overexpression inhibited TGF-β-induced Smad-responsive reporter activity and targeted TGF-β type I receptor ALK5 for lysosomal degradation in mammalian cells, demonstrating evolutionarily conserved negative regulation of TGF-β/Nodal signaling. Overexpression in mammalian cells with Smad-reporter assays, receptor degradation assays, and zebrafish embryo overexpression FASEB journal Medium 17197390
2010 Dact2 is specifically expressed in ureteric bud/collecting duct epithelium of the developing mouse kidney; siRNA knockdown in collecting duct cells resulted in constitutive phospho-Smad2, elevated TGF-β-induced phospho-Smad2, defective actomyosin cable assembly at the leading edge during wound healing, and abnormal cyst/tubule morphology in 3D culture, placing Dact2 as a negative regulator of TGF-β signaling controlling collecting duct morphogenesis. siRNA knockdown, phospho-Smad2 immunoblotting, monolayer wound-healing assay, 3D culture morphology, immunofluorescence American journal of physiology. Renal physiology Medium 20685821
2013 DACT2 suppresses canonical Wnt signaling in lung cancer cells by inhibiting TCF/LEF transcriptional activity; its expression is silenced by promoter CpG hypermethylation, and restoration of DACT2 reduces β-catenin expression and inhibits tumor proliferation in vitro and in xenograft models. Methylation-specific PCR, western blotting, siRNA knockdown, TCF/LEF reporter assay, xenograft mouse model The Journal of pathology Medium 22806826
2013 Dact2 inhibits the canonical Wnt signaling pathway in odontogenesis by physically interacting with the transcription factor PITX2, repressing PITX2-driven activation of downstream targets (Dlx2 and amelogenin promoters) and attenuating PITX2-mediated Topflash Wnt reporter activity; Pitx2 in turn endogenously activates Dact2 expression forming a feedback loop. Co-immunoprecipitation, transient transfection, Topflash reporter assay, loss-of-function/gain-of-function studies, immunohistochemistry PloS one Medium 23349981
2013 DACT2 suppresses hepatocellular carcinoma by inhibiting Wnt signaling: re-expression suppressed TCF-4 transcriptional activity and Wnt downstream gene expression, induced G2-M arrest, and inhibited xenograft tumor growth; depletion of DACT2 reactivated TCF-4 activity. TCF-4 reporter assay, flow cytometry, siRNA knockdown, xenograft nude mice, western blotting Epigenetics Medium 23449122
2014 DACT2 restoration in papillary thyroid cancer cells (TPC-1) decreased β-catenin, c-Myc, cyclinD1, and MMP-9 and increased phospho-β-catenin, inhibited TCF/LEF activity in wild-type or mutant β-catenin contexts, and suppressed proliferation, invasion, and migration; co-transfection of DACT2 with Dvl2 increased TCF/LEF activity, indicating Dact2 modulates β-catenin phosphorylation and acts upstream of the TCF/LEF complex. TCF/LEF reporter assay, western blotting, siRNA knockdown, co-transfection, migration/invasion assays PloS one Medium 25375359
2014 DACT2 inhibits both canonical and noncanonical WNT signaling in gastric cancer cells (SGC7901) and suppresses gastric cancer xenograft growth; restoration of DACT2 expression also inhibited cell proliferation, migration, and invasion. siRNA, colony formation assay, flow cytometry, immunofluorescence, xenograft mouse model, WNT reporter assays American journal of cancer research Medium 25520862
2016 DACT2 inhibits esophageal cancer growth by suppressing Wnt signaling; its expression is silenced by promoter hypermethylation, and restoration suppressed colony formation, migration, invasion, and xenograft tumor growth. MSP, 5-aza treatment, colony formation, migration/invasion assays, xenograft model Oncotarget Medium 26919254
2016 DACT2 ectopic expression in breast cancer cells induced apoptosis, inhibited proliferation and migration, suppressed EMT, and acted through antagonizing both Wnt/β-catenin and Akt/GSK-3 signaling pathways. Ectopic expression, apoptosis assays, migration assays, western blotting for pathway components, EMT marker analysis Oncotarget Medium 27708215
2017 DACT2 overexpression in glioma cells suppressed proliferation and induced apoptosis by increasing phospho-YAP and phospho-β-catenin, preventing YAP nuclear translocation and sequestering it in the cytoplasm for degradation, placing DACT2 upstream of the YAP pathway via Wnt/β-catenin signaling. Overexpression and knockdown, flow cytometry, western blotting, nuclear/cytoplasmic fractionation, xenograft model Cell death & disease Medium 28796248
2018 DACT2 ectopic expression in NPC cells induced G2/M arrest by directly suppressing β-catenin/Cdc25c signaling, which sensitized cells to paclitaxel and 5-FU but not cisplatin; DACT2 also suppressed proliferation, migration, and invasion through downregulation of matrix metalloproteinases. Flow cytometric analysis, immunofluorescence, western blotting, dual-luciferase reporter assay, colony formation, chemosensitivity assay Clinical epigenetics Medium 30359298
2018 TET1, a 5-methylcytosine dioxygenase, promotes demethylation of the DACT2 promoter in NPC cells, restoring DACT2 expression and thereby antagonizing Wnt/β-catenin signaling as part of TET1's tumor suppressor mechanism. Ectopic TET1 expression, MSP, RT-PCR, western blotting for nuclear β-catenin and downstream targets Clinical epigenetics Medium 30075814
2019 The DACT2 promoter SNP rs9364433 modulates DACT2 expression through allele-specific binding of transcription factor TFAP2A; the G allele reduces TFAP2A binding and decreases DACT2 expression in NSCLC cells, establishing TFAP2A as a transcriptional activator of DACT2. Luciferase reporter gene assay, EMSA (Electrophoretic Mobility Shift Assay), genotyping, in vitro and in vivo DACT2 expression analysis Biochemical pharmacology Medium 31866302
2020 DACT2 knockout in zebrafish (10-bp deletion via CRISPR-Cas9) enhanced expression of MMP2, MMP9, Snail, VEGF, and ZEB (EMT-related genes), caused gastrointestinal epithelial hyperplasia, pancreatic/hepatic fibrosis, and accelerated wound healing via EMT, establishing Dact2 as a negative regulator of EMT-related gene expression in vivo. CRISPR-Cas9 knockout zebrafish, RT-PCR, histology, wound healing assay Biochemical and biophysical research communications Medium 31983425
2020 DACT2 overexpression in HL-1 cardiac cells facilitated β-catenin accumulation by reducing its phosphorylation at Thr41/Ser45, and inhibited TGF-β signaling in primary atrial fibroblasts, reducing collagen I and III expression and regulating ion channel gene expression (increased KCNE5, decreased KCNH2 and SCN5A). Western blotting, RT-PCR, overexpression in HL-1 cells and primary atrial fibroblasts Journal of thoracic disease Low 32642106
2021 miR-181a targets MLL3, a histone methyltransferase, downregulating it in PTC cells; this leads to decreased DACT2 expression and upregulation of YAP and VEGF, promoting angiogenesis, placing DACT2 downstream of MLL3 in an exosomal miR-181a/MLL3/DACT2/YAP-VEGF axis. miRNA mimic/inhibitor transfection, siRNA knockdown of MLL3, exosome extraction and treatment, in vitro tube formation and proliferation assays, in vivo tumor growth Molecular therapy. Nucleic acids Medium 33898109
2022 DACT2 overexpression in lung myofibroblasts inhibited TGF-β-induced myofibroblast differentiation by promoting lysosome-mediated degradation of LDHA, thereby suppressing glycolysis (reduced glucose uptake, extracellular acidification rate, lactate, and ATP); AAV6-mediated DACT2 overexpression attenuated experimental pulmonary fibrosis in vivo. AAV6 overexpression in vivo, TGF-β-induced differentiation assays, LDHA degradation rate monitoring, lysosome colocalization, metabolic flux assays (ECAR, OCR, ATP, lactate) International journal of biological macromolecules Medium 36481337
2022 DACT2 inhibits liver fibrosis by suppressing TGF-β/Smad signaling and Wnt/β-catenin signaling in HSC-T6 cells; lentiviral overexpression of DACT2 reduced α-SMA, TGF-β1, Smad3, β-catenin, and CyclinD1 protein levels, and decreased MMP-2 and TIMP-1 expression, while also attenuating CCl4-induced liver fibrosis in vivo. Lentiviral overexpression, western blotting (α-SMA, TGF-β1, Smad3, Smad7, β-catenin, CyclinD1), RT-PCR (MMP-2, TIMP-1), CCl4 liver fibrosis mouse model, histology Cellular and molecular biology Low 35818217
2023 Dact2 knockout mice show elevated Igf1 expression (a Wnt target gene) with β-catenin directly binding and regulating Igf1 transcription; cisplatin-induced nephrotoxicity was alleviated in Dact2 KO mice through reduced apoptosis and downregulation of proapoptotic MAPK signaling, establishing a Dact2/Wnt/β-catenin/Igf1-MAPK axis in kidney injury response. Dact2 KO mouse model, RNA sequencing, western blotting, ChIP/β-catenin binding to Igf1 locus, Igf1 knockdown, Wnt agonist CHIR-99021 treatment Cell biology and toxicology Medium 37603122

Source papers

Stage 0 corpus · 37 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 Identification and characterization of human DAPPER1 and DAPPER2 genes in silico. International journal of oncology 141 12632086
2006 The evolutionally conserved activity of Dapper2 in antagonizing TGF-beta signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 57 17197390
2013 Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. The Journal of pathology 54 22806826
2018 The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via β-catenin/Cdc25c signaling and G2/M arrest. Clinical epigenetics 38 30359298
2021 miR-181a, delivered by hypoxic PTC-secreted exosomes, inhibits DACT2 by downregulating MLL3, leading to YAP-VEGF-mediated angiogenesis. Molecular therapy. Nucleic acids 36 33898109
2014 DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. American journal of cancer research 36 25520862
2013 Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma. Epigenetics 33 23449122
2018 TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt/β-catenin signaling pathway in nasopharyngeal carcinoma cells. Clinical epigenetics 31 30075814
2014 Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling. PloS one 31 25375359
2017 DACT2 Epigenetic Stimulator Exerts Dual Efficacy for Colorectal Cancer Prevention and Treatment. Pharmacological research 29 29199082
2016 Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling. Oncotarget 27 26919254
2016 DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells. Oncotarget 26 27708215
2021 Exosomal microRNA-503-3p derived from macrophages represses glycolysis and promotes mitochondrial oxidative phosphorylation in breast cancer cells by elevating DACT2. Cell death discovery 25 34016964
2013 Dact2 represses PITX2 transcriptional activation and cell proliferation through Wnt/beta-catenin signaling during odontogenesis. PloS one 24 23349981
2010 Dact2 is expressed in the developing ureteric bud/collecting duct system of the kidney and controls morphogenetic behavior of collecting duct cells. American journal of physiology. Renal physiology 19 20685821
2019 DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Biochemical pharmacology 18 31866302
2017 Upregulation of DACT2 suppresses proliferation and enhances apoptosis of glioma cell via inactivation of YAP signaling pathway. Cell death & disease 18 28796248
2017 Methylation of DACT2 promotes breast cancer development by activating Wnt signaling. Scientific reports 17 28607412
2022 CircDUSP1 regulates tumor growth, metastasis, and paclitaxel sensitivity in triple-negative breast cancer by targeting miR-761/DACT2 signaling axis. Molecular carcinogenesis 16 36562476
2020 Dact2 is involved in the regulation of epithelial-mesenchymal transition. Biochemical and biophysical research communications 16 31983425
2015 Expression and epigenetic regulation of DACT1 and DACT2 in oral squamous cell carcinoma. Cancer biomarkers : section A of Disease markers 16 25524937
2022 DACT2 protects against pulmonary fibrosis via suppressing glycolysis in lung myofibroblasts. International journal of biological macromolecules 13 36481337
2005 Identification and characterization of rat Dact1 and Dact2 genes in silico. International journal of molecular medicine 12 15870912
2017 Methylation of DACT2 contributes to the progression of breast cancer through activating WNT signaling pathway. Oncology letters 10 29435071
2013 Reduced expression of DACT2 promotes hepatocellular carcinoma progression: involvement of methylation-mediated gene silencing. World journal of surgical oncology 10 23496880
2005 Regulation of the early expression patterns of the zebrafish Dishevelled-interacting proteins Dapper1 and Dapper2. Developmental dynamics : an official publication of the American Association of Anatomists 9 15765513
2018 MicroRNA-214 promotes the proliferation, migration and invasion of gastric cancer MKN28 cells by suppressing the expression of Dact2. Experimental and therapeutic medicine 7 30542447
2020 DACT2 regulates structural and electrical atrial remodeling in atrial fibrillation. Journal of thoracic disease 6 32642106
2024 DACT2 modulates atrial fibrillation through TGF/β and Wnt signaling pathways. Heliyon 5 39224277
2023 Loss of Dact2 alleviates cisplatin-induced nephrotoxicity through regulation of the Igfl-MAPK pathway axis. Cell biology and toxicology 5 37603122
2021 Diagnostic value of DACT-2 methylation in serum of prostate cancer patients. Annals of palliative medicine 5 33440955
2019 Downregulation of DACT-2 by Promoter Methylation and its Clinicopathological Significance in Prostate Cancer. Journal of Cancer 5 31205531
2018 Association between promoter hypermethylation of the DACT2 gene and tumor stages in breast cancer. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 4 29745077
2023 Different expression of DACT1, DACT2, and CYCLIN D1 genes in human colorectal cancer tissues and its association with clinicopathological characteristics. Nucleosides, nucleotides & nucleic acids 3 37610179
2022 188Rhenium Treatment Induces DACT2 Expression in Hepatocellular Carcinoma Cells. Cell journal 3 35717568
2022 Mechanism of dact2 gene inhibiting the occurrence and development of liver fibrosis. Cellular and molecular biology (Noisy-le-Grand, France) 3 35818217
2019 Investigating the methylation status of DACT2 gene and its association with MTHFR C677T polymorphism in patients with colorectal cancer. Molecular biology research communications 2 31531376

Missed literature

Know a paper Affinage missed for DACT2? Flag it for the maintainers and the community.

No submissions yet.